Variant Gene Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1566734
rs1566734
0.700 GeneticVariation UNIPROT The tyrosine phosphatase PTPRJ/DEP-1 genotype affects thyroid carcinogenesis. 15378013

2004

dbSNP: rs121434507
rs121434507
0.700 GeneticVariation UNIPROT Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. 12089527

2002

dbSNP: rs1566734
rs1566734
0.700 GeneticVariation UNIPROT Ptprj is a candidate for the mouse colon-cancer susceptibility locus Scc1 and is frequently deleted in human cancers. 12089527

2002

dbSNP: rs119490107
rs119490107
0.700 GeneticVariation UNIPROT Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. 10362364

1999

dbSNP: rs28936407
rs28936407
0.700 GeneticVariation UNIPROT Loss-of-function mutations in PPAR gamma associated with human colon cancer. 10394368

1999

dbSNP: rs121434623
rs121434623
0.700 GeneticVariation UNIPROT Chromosomal localization of the protein tyrosine phosphatase G1 gene and characterization of the aberrant transcripts in human colon cancer cells. 7509295

1994

dbSNP: rs1114167435
rs1114167435
0.700 CausalMutation CLINVAR

dbSNP: rs121913341
rs121913341
0.700 GeneticVariation UNIPROT

dbSNP: rs121913355
rs121913355
0.700 GeneticVariation UNIPROT

dbSNP: rs137853007
rs137853007
0.700 GeneticVariation UNIPROT

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Mechanisms of Acquired Resistance to BRAF V600E Inhibition in Colon Cancers Converge on RAF Dimerization and Are Sensitive to Its Inhibition. 28951457

2018

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE We used a shRNA-based genetic screen focused on genes upregulated in BRAF(V600E) CCs to identify vulnerabilities of this tumor subtype that might be exploited therapeutically. 27058664

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE BRAF (V600E) and KRAS mutations were analyzed in node-positive colon cancer patients (n = 3305) treated with FOLFOX-based chemotherapy in an adjuvant trial (Alliance N0147). 26160882

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE TFF2-CXCR4 Axis Is Associated with BRAF V600E Colon Cancer. 25899003

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE In conclusion, our findings suggest that targeting ErbB-3 receptors could represent an effective therapeutic approach in BRAF-V600E mutant colon cancer. 26160848

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE The mutational status of KRAS and BRAF(V600E) oncogenes combined with analysis of the DNA mismatch repair system with/without the CpG island methylator phenotype (CIMP) has been shown to identify colon cancer subtypes with distinct clinical features and prognoses. 26872400

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon cancers are intrinsically resistant to these drugs because of feedback activation of EGFR. 26365186

2016

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE BRAF V600E was associated with advanced TNM (P < 0.001), more distant metastases (P = 0.025), and worse overall survival (OS, P < 0.001; multivariate HR = 4.2, P = 0.004) in colon cancer patients. 25367198

2015

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Female patients and older group harbored a higher KRAS mutation (P = 0.018 and P = 0.031, respectively); BRAF (V600E) mutation showed a higher frequency in colon cancer and poor differentiation tumors (P = 0.020 and P = 0.030, respectively); proximal tumors appeared a higher PIK3CA mutation (P<0.001) and distant metastatic tumors shared a higher NRAS mutation (P = 0.010). 24339949

2015

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE KRAS and BRAF (V600E) mutations are important predictive and prognostic markers, respectively, in colon cancer, but little is known about patient and clinical factors associated with them. 24925349

2014

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE MSI and the BRAF(V600E) mutation have a prognostic impact in colon cancer. 24964758

2014

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Sorafenib and cetuximab therapy led to a mixed radiographic response with some areas showing dramatic improvement and other areas showing stable disease over a 7-month period which is a notably long period of progression-free survival for V600E BRAF mutated colon cancer. 23792568

2014

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE The clinical studies in the manuscript by Al-Marrawi et al. describe the rational combination of signaling inhibitors in a colon cancer patient whose tumor cells express a mutant active B-RAF V600E protein that signals into the MEK1/2-ERK1/2 pathway downstream of K-RAS; this is a particularly aggressive form of colon cancer for which few rational therapeutic interventions have been available until recent times. 24025253

2014

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE In contrast, colon cancers that harbour the same BRAF(V600E) mutation are intrinsically resistant to BRAF inhibitors, due to feedback activation of the epidermal growth factor receptor (EGFR). 24670642

2014

dbSNP: rs113488022
rs113488022
0.100 GeneticVariation BEFREE Colon cancers from 2008 to 2012 tested by pyrosequencing for BRAF V600E mutation were selected. 23650027

2013